Conditional Reprogramming: Modeling Urological Cancer and Translation to Clinics

Wei Liu,Lingao Ju,Songtao Cheng,Gang Wang,Kaiyu Qian,Xuefeng Li,Yu Xiao,Xinghuan Wang
DOI: https://doi.org/10.1002/ctm2.95
IF: 8.554
2020-01-01
Clinical and Translational Medicine
Abstract:Abstract Patient‐derived models, including cell models (organoids and conditionally reprogrammed cells [CRCs]) and patient‐derived xenografts, are urgently needed for both basic and translational cancer research. Conditional reprogramming (CR) technique refers to a co‐culture system of primary human normal or tumor cells with irradiated murine fibroblasts in the presence of a Rho‐associated kinase inhibitor to allow the primary cells to acquire stem cell properties and the ability to proliferate indefinitely in vitro without any exogenous gene or viral transfection. Considering its robust features, the CR technique may facilitate cancer research in many aspects. Under in vitro culturing, malignant CRCs can share certain genetic aberrations and tumor phenotypes with their parental specimens. Thus, tumor CRCs can promisingly be utilized for the study of cancer biology, the discovery of novel therapies, and the promotion of precision medicine. For normal CRCs, the characteristics of normal karyotype maintenance and lineage commitment suggest their potential in toxicity testing and regenerative medicine. In this review, we discuss the applications, limitations, and future potential of CRCs in modeling urological cancer and translation to clinics.
What problem does this paper attempt to address?